December 27, 2016Clinical and Applied Thrombosis/HemostasisOpen Access

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience

View Full Paper

Ask AI

Bookmark

Why the study?

Does rivaroxaban safely and effectively treat symptomatic venous thromboembolism in patients with active cancer?

Structured PICO

Does rivaroxaban safely and effectively treat symptomatic venous thromboembolism in patients with active cancer?

Population

400 patients with active cancer and associated symptomatic venous thromboembolism (deep venous thrombosis and/or pulmonary embolism), 55.8% female. 90.5% had solid tumors and 61% had metastatic disease.

Intervention

Rivaroxaban (either following initial parenteral enoxaparin for median 3 days, or on-label rivaroxaban treatment)

Outcome

Incidence of recurrent symptomatic VTE (efficacy) and major bleeding (safety) throughout the treatment with rivaroxabanhard clinical

In a retrospective cohort of 400 patients with active cancer and VTE, rivaroxaban demonstrated a 3.25% recurrence rate and 5.5% major bleeding rate, suggesting it is a viable alternative for cancer-associated thrombosis.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Rivaroxaban may offer a convenient option for cancer-associated VTE; leaves open need for randomized comparisons versus LMWH.

Cite This Study

Pignataro et al. (2016) studied this question.

synapsesocial.com/papers/6a737d24007d73ca2ffb6603 https://doi.org/10.1177/1076029616677800

View Full Paper

Ask AI

Bookmark

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience

Structured PICO

Discussion

Implication

Cite This Study

Oral Rivaroxaban for the Treatment of Symptomatic Venous Thromboembolism in 400 Patients With Active Cancer: A Single-Center Experience

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider